Sab Biotherapeutics, Inc. · NASDAQ:SABS
Caligan Partners LP reported a 8.80% stake in Sab Biotherapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2026 · Filed Aug 14, 2026
Caligan Partners LP reported a 8.80% stake in Sab Biotherapeutics, Inc., 7,967,207 shares, as a passive investor on Jun 30, 2026. Filed Aug 14, 2026 (Schedule 13G/A).
- Stake
- 8.80%
- Shares
- 7,967,207
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 2 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Caligan Partners LP | 8.80% | 7,967,207 |
| JOHNSON DAVID EDWARD | 8.80% | 7,967,207 |
Source
Related
- Sab Biotherapeutics, Inc.
- Caligan Partners LP
- Sab Biotherapeutics, Inc. shareholders
- Schedule 13G · Caligan Partners LP · May 15, 2026
- Form 4 · Kropotova Alexandra · Sep 18, 2026
- Schedule 13G/A · Vivo Opportunity, LLC · Aug 14, 2026
- Schedule 13G/A · Woodline Partners LP · Aug 14, 2026
- Schedule 13G/A · Balyasny Asset Management L.P. · Aug 14, 2026
- Schedule 13G/A · Commodore Capital LP · Aug 14, 2026